To Go Against Nature: Manipulating the Neonatal Ductus Arteriosus with Prostaglandin

Newborn and Infant Nursing Reviews

Volumn 6, Issue 3, 2006, Pages 158-162

  Chamberlin, Melissa ^a   Lozynski, Jennifer ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Cardiac; Congenital heart disease; Ductus arteriosus; Neonate; Prostaglandin

Indexed keywords

EID: 33747756105     PISSN: 15273369     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.nainr.2006.05.001     Document Type: Article

References (35)

1. Hammerman C. Patent ductus arteriosus: clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 22 (1995) 457-477
2. Roehl S.L., and Townsend R.J. Alprostadil (Prostin VR pediatric sterile solution, the Upjohn Company). Drug Intell Clin Pharm 16 (1982) 823-832
3. Clyman R.I. Ductus arteriosus: current theories of prenatal and postnatal regulation. Semin Perinatol 11 (1987) 64-71
4. Reller M.D., Rice M.J., and McDonald R.W. Review of studies evaluating ductal patency in the premature infant. J Pediatr 122 (1993) s59-s62
5. Gentile R., Stevenson G., Dooley T., et al. Pulsed Doppler echocardiographic determination of the time of ductal closure in normal newborn infants. J Pediatr 98 (1981) 443-448
6. Lim M.K., Hanretty K., Houston A.B., et al. Intermittent ductal patency in healthy newborn infants: demonstration by colour Doppler flow mapping. Arch Dis Child 67 10 Spec No (1992) 1217-1218
7. Leonhardt A., Glaser A., Wegmann M., et al. Expression of prostanoid receptors in human ductus arteriosus. Br J Pharmacol 138 (2003) 655-659
8. Smith G.C. The pharmacology of the ductus arteriosus. Pharmacol Rev 50 (1998) 35-58
9. Van Overmeire B., and Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 10 (2005) 177-184
10. Elliott R.B., Starling M.B., and Neutze J.M. Medical manipulation of the ductus arteriosus. Lancet 1 (1975) 140-142
11. 1 in aortic arch abnormalities. Circulation 59 (1979) 169-173
12. 1 in suspected ductus dependent cardiac malformation. Arch Dis Child 59 (1984) 1020-1026
13. Penny D.J., and Shekerdemian L.S. Management of the neonate with symptomatic congenital heart disease. Arch Dis Child Fetal Neonatal Ed 84 (2001) F141-F145. http://www.archdischild.com [Retrieved February, 2006 from www.archdischild.com]
14. Taketomo C.K., Hoding J.H., and Kraus D.M. Pediatric dosage handbook: including neonatal dosing, drug administration & extemporaneous preparations. 10th ed. (2003), Lexi-Comp, Hudson (Ohio)
15. Zenk K.E., Sills J.G., and Koeppel R.M. Neonatal medications and nutrition. 3rd ed. (2003), NICU Ink, Santa Rosa (Calif)
16. 1 in man. J Clin Invest 56 (1975) 1404-1410
17. 1 treatment for ductus dependent congenital heart disease. Eur J Pediatr 154 (1995) 700-707
18. 1 administered by intravenous infusion in human subjects. Eur J Clin Pharmacol 46 (1994) 275-277
19. Barst R.J., and Gersony W.M. The pharmacologic treatment of patent ductus arteriosus: a review of the evidence. Drugs 38 (1989) 249-266
20. 1 derivative (OP-1206) in an infant with double outlet right ventricle and pulmonary stenosis. Effect on ductus-dependent pulmonary circulation. Jpn Heart J 32 (1991) 735-740
21. 1 incorporated in lipid microspheres on the rat ductus arteriosus. Jpn J Pharmacol 81 (1999) 107-114
22. 1 therapy for diaphragmatic hernia. Eur J Pediatr 152 (1993) 877-879
23. Mandai H., Kinouchi K., Kawaraguchi Y., et al. An extremely low birth weight infant with pulmonary atresia complicated with necrotizing enterocolitis. Masui 50 (2001) 1133-1135
24. 1 infusion. Pediatrics 112 1 Pt 1 (2003) e27-e29
25. Product information. Prostin VR pediatric (1995), The UpJohn Company, Kalamazoo (Mich)
26. 1 in infants with critical congenital heart disease. Circulation 64 (1981) 893-898
27. Miller S.F. Resolution of calcific brown fat necrosis associated with prostaglandin therapy for cyanotic congenital heart disease in neonates: report of two cases. Pediatr Radiol 34 11 (2004) 919-923
28. 1 in neonates. J Pediatr 138 (2001) 263-265
29. 1. Pediatr Dermatol 17 (2000) 58-61
30. Kaufman MB, El-Chaar GM. Bone and tissue changes following prostaglandin therapy in neonates. Ann Pharmacother 1996;30:269-74,277.
31. Peled N., Dagan O., Babyn P., et al. Gastric-outlet obstruction induced by prostaglandin therapy in neonates. N Engl J Med 327 (1992) 505-510
32. Joshi A., Berdon W.E., Brudnicki A., et al. Gastric thumbprinting: diffuse gastric wall mucosal and submucosal thickening in infants with ductal-dependent cyanotic congenital heart disease maintained on long-term prostaglandin therapy. Pediatr Radiol 32 (2002) 405-408
33. 1 treatment. Pediatr Pathol 7 (1987) 165-173
34. Tappero E.P., and Honeyfield M.E. Physical assessment of the newborn: a comprehensive approach to the art of physical examination. 3rd ed. (2003), NICU Ink, Santa Rosa (Calif)
35. 1 therapy. Neonatal Netw 12 (1993) 17-22